Innovative Therapeutic Solutions for CNS Disorders and Orphan Diseases

Spotlight on ZX008

Our lead investigational product candidate is ZX008, a low-dose fenfluramine for the treatment of Dravet syndrome. Dravet syndrome is a rare and catastrophic form of epilepsy that begins in infancy, with life threatening consequences for patients and for which current treatment options are very limited. ZX008 has received orphan drug designation in the United States and Europe.

more »